# Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tildrakizumab-versus-placebo-or-etanercept-for-chronic-plaque-psoriasis/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kristian Reich,Kim Papp,Andrew Blauvelt,Stephen K. Tyring,Rodney Sinclair,Diamant Thaçi,Kristine Nograles,Anish Mehta,N. Cichanowitz,Qing Li,Kenneth Liu,Carmen La Rosa,Stuart Green,Alexa B. Kimball |
| Citations | 563 |
| DOI | 10.1016/s0140-6736(17)31279-5 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2623888527 |
| PMID | 28596043 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Alexa B. Kimball](https://scholariq.org/researchers/alexa-b-kimball/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.